m
Recent Posts
Connect with:
Tuesday / June 25.

Eylea

Eylea (aflibercept) binds to vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PLGF) proteins.1

Eylea is listed on the Australian Pharmaceutical Benefits Scheme for five indications in adults: neovascular age-related macular degeneration; visual impairment due to macular oedema secondary to central retinal vein occlusion and branch retinal vein occlusion; diabetic macular oedema; and visual impairment due to myopic choroidal neovascularisation.1,2

Evidence for Eylea is based on randomised controlled trials, real-world, and post-marketing experience, in addition to more than eight million patient-years’ exposure.1, 3-10

Contact: Bayer Account Manager

PBS Information: Authority required for the treatment of wet age-related macular degeneration, diabetic macular oedema, central retinal vein occlusion and branch retinal vein occlusion, myopic choroidal neovascularisation. Refer to PBS schedule for full Authority Required information.

Please refer to the Product Information before prescribing. Approved PI available by scanning the QR code or upon request from Bayer Medical Information on (AUS) 1800 008 757. Prepared March 2024. PP-EYL-AU-0XXX.

References

  1. Eylea Australian Approved Product Information.
  2. Pharmaceutical Benefits Scheme: pbs.gov.au.
  3. Lukic, M., Williams, G., Rajendram, R., et al., Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes. Eur J Ophthalmol. 2021 May;31(3):1201–1207. DOI: 10.1177/1120672120925034.
  4. Eleftheriadou, M., Gemenetzi, M., Patel, P.J., et al., Three-year outcomes of aflibercept treatment for neovascular age-related macular degeneration: Evidence from a clinical setting. Ophthalmol Ther. 2018 Dec;7(2):361–368. DOI: 10.1007/s40123-018-0139-5.
  5. Traine, P.G., Pfister, I.B., Garweg, J.G., et al., Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend” regimen. Ophthalmol Retina. 2019 May;3(5):393–399. DOI: 10.1016/j.oret.2019.01.018.
  6. Sheu, S.J., Yang, C.H., Chen SJ. et al., One-year outcomes of the treat-and-extend regimen using aflibercept for the treatment of diabetic macular edema. J Chin Med Assoc. 2022 Feb 1;85(2):246– 251. DOI: 10.1097/JCMA.0000000000000680..
  7. Kim, Y.C., Shin, J.P., Lee, J.E., Two-year outcomes of the treat-and-extend regimen using aflibercept for treating diabetic macular oedema. Sci Rep. 2020 Dec 16;10(1):22030. DOI: 10.1038/s41598-020-78954-3.
  8. Hirano, T., Toriyama, Y., Takamura, Y. et al., Outcomes of a 2-year treat-and-extend regimen with aflibercept for diabetic macular edema. Sci Rep 11, 4488 (2021). DOI: 10.1038/s41598-021-83811-y.
  9. Ohji, M., Takahashi, K., Terano, Y. et al., ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: A randomized controlled trial. Adv Ther. 2020 Mar;37(3):1173–1187. DOI: 10.1007/s12325-020-01236-x.
  10. Eylea. Data on file. January 2023(v1.0).

This article is restricted to
Verified Health Practitioners only

Already registered?